Geoffrey Chong
YOU?
Author Swipe
View article: Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study Open
The presence of a single large disease site or so-called tumor ‘bulk’ in lymphoma has been variably associated with outcomes and influenced management decisions. However, challenges arise in using bulk as a prognosticator due to varied def…
View article: T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL Open
View article: Immunotherapy in gastric adenocarcinoma – a rapidly evolving treatment landscape
Immunotherapy in gastric adenocarcinoma – a rapidly evolving treatment landscape Open
Gastric cancer (GC) ranks as the fifth most common cancer diagnosed worldwide. Despite advances in treatment, the prognosis for patients remains poor. Immune checkpoint inhibitors have been increasingly utilised across all settings in the …
View article: 37P Efficacy and safety of fruquintinib vs placebo by metastatic site in metastatic colorectal cancer: A FRESCO-2 subgroup analysis
37P Efficacy and safety of fruquintinib vs placebo by metastatic site in metastatic colorectal cancer: A FRESCO-2 subgroup analysis Open
View article: T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Open
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffecti…
View article: 146 | PHASE 1/2 STUDIES OF DZD8586 IN CLL/SLL PATIENTS AFTER COVALENT OR NON‐COVALENT BTK INHIBITORS AND BTK DEGRADERS
146 | PHASE 1/2 STUDIES OF DZD8586 IN CLL/SLL PATIENTS AFTER COVALENT OR NON‐COVALENT BTK INHIBITORS AND BTK DEGRADERS Open
View article: 242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY Open
View article: 425 | BIOMARKER ANALYSES OF THE INFLAMMATORY PROFILE AND MRD IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA VERSUS FOLLICULAR LYMPHOMA TREATED WITH ODRONEXTAMAB
425 | BIOMARKER ANALYSES OF THE INFLAMMATORY PROFILE AND MRD IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA VERSUS FOLLICULAR LYMPHOMA TREATED WITH ODRONEXTAMAB Open
View article: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse la…
View article: Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia
Factors associated with thrombosis among solid organ cancer patients in Kuala Lumpur, Malaysia Open
This study highlights the prevalence of CAT at baseline and the incidence of CAT during follow-up, similar to other studies. Patients' clinical characteristics were associated with CAT at baseline while disease and treatment factors were a…
View article: Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2 Open
Background Fruquintinib is a highly selective, oral inhibitor of all 3 VEGF receptors. The global, randomized, double-blind phase 3 FRESCO-2 trial (NCT04322539) met its primary endpoint demonstrating significantly improved overall survival…
View article: Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study Open
Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus placebo.
View article: Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study Open
Follicular lymphoma (FL) outcomes are influenced by host immune activity. CD20-directed therapy plus programmed cell death 1 inhibition (PD-1i) increases T-cell tumor killing and natural killer cell antibody-dependent cell cytotoxicity. Mo…
View article: Incidence of Venous Thromboembolism and Its Associated Risk Factors in Newly Diagnosed Multiple Myeloma Patients in the Klang Valley, Malaysia
Incidence of Venous Thromboembolism and Its Associated Risk Factors in Newly Diagnosed Multiple Myeloma Patients in the Klang Valley, Malaysia Open
Background: Venous thromboembolism (VTE) is a potentially severe medical problem among multiple myeloma (MM) patients, with evolving treatment regimens potentially increasing the thrombotic risk. Data on VTE incidence and risk factors in m…
View article: Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy
Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy Open
Not available.
View article: Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review Open
Tumor “bulk” has historically been considered an important prognostic marker and a clinical tool to guide treatment in patients with lymphoma. However, its use and definitions in trial designs vary significantly, and it is unclear how this…
View article: Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI Open
Background Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably predicted. The International PCNSL Collaborative Group developed standardized response assessme…
View article: Prognostic Utility of Quantitative Pet Parameters on Baseline and Interim Fdg-Pet Scans in Hodgkin Lymphoma
Prognostic Utility of Quantitative Pet Parameters on Baseline and Interim Fdg-Pet Scans in Hodgkin Lymphoma Open
View article: PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma
PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma Open
Anthracycline-mediated cardiotoxicity is a common concern after lymphoma therapy, particularly in patients with high cardiovascular risk (CVR). In noncancer populations, coronary artery calcium scoring (CACS) effectively identifies individ…
View article: Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer
Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer Open
Background Immunotherapy has emerged as a standard treatment for deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC). Pembrolizumab became widely available as a first‐line (1L) option in Australia following the Pharmaceuti…
View article: The value of semiquantitative <scp>PET</scp> features and end‐of‐therapy <scp>PET</scp> in grade <scp>3B</scp> follicular lymphoma
The value of semiquantitative <span>PET</span> features and end‐of‐therapy <span>PET</span> in grade <span>3B</span> follicular lymphoma Open
Summary Grade 3B follicular lymphoma (G3BFL) is a rare lymphoma thought to sit on a continuum between low‐grade FL and diffuse large B‐cell lymphoma (DLBCL). The prognostic impact of quantitative positron emission tomography (PET) metrics …
View article: Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma Open
View article: Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era Open
Population‐based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age‐standardised incidence ratios (SIRs) of second primary malignancies …
View article: Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study Open
Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d’Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burde…
View article: Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project
Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project Open
Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B‐cell lymphoma (RR‐DLBCL) based on positive results of the landmark phase II randomised G029365 tria…
View article: Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma Open
View article: Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma Open
18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is a valuable prognostic tool in modern lymphoma care. In this study, we explored the use of quantitative FDG-PET parameters in predicting the histology of suspected relapsed or…
View article: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY
POLATUZUMAB, BENDAMUSTINE & RITUXIMAB EFFICACY IN RELAPSED/REFRACTORY TRIAL‐INELIGIBLE LARGE B CELL LYMPHOMA PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY Open
Introduction: RRDLBCL outcomes remain poor despite autologous transplant and CAR-T therapies offering potential cure to a minority. Evidence for current therapies is mostly from phase II trials with stringent eligibility criteria. Applicab…
View article: Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study
Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study Open
Introduction: DLBCL & FL are exquisitely radiosensitive. RT offers durable in-field remissions & good palliation in relapsed/refractory (RR) disease. RT also stimulates anti-tumour immunity through several mechanisms and is synergistic wit…
View article: Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Data from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study Open
Purpose:To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC).Patients and Methods:This open-label phase II stud…